BioSyent Inc. (CVE:RX – Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday. The company traded as high as C$17.41 and last traded at C$17.37, with a volume of 3,329 shares traded. The stock had previously closed at C$17.15.
BioSyent Trading Up 1.1%
The company has a quick ratio of 6.91, a current ratio of 2.07 and a debt-to-equity ratio of 6.85. The firm’s 50-day moving average price is C$16.45 and its 200 day moving average price is C$15.02. The company has a market capitalization of C$194.76 million, a P/E ratio of 20.30 and a beta of 1.05.
Insider Activity at BioSyent
In other news, Director Seyed Ahmad Ashrafi sold 2,900 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of C$16.55, for a total value of C$47,995.00. Following the completion of the sale, the director directly owned 21,461 shares of the company’s stock, valued at C$355,179.55. This represents a 11.90% decrease in their ownership of the stock. Insiders sold 7,251 shares of company stock valued at $118,207 over the last three months. Corporate insiders own 33.65% of the company’s stock.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Further Reading
- Five stocks we like better than BioSyent
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
